As of October 31, a total of 461 A-share pharmaceutical companies disclosed their performance in the third quarter of 2022, and more than 40% of them achieved revenue and net profit in
the first three quarters.
In terms of net profit, 23 pharmaceutical companies achieved net profits of more than 2 billion yuan in the first three quarters, of which 4 companies had net profits of more than 5 billion yuan, namely Jiuan Medical, Mindray Medical, WuXi AppTec, and Zhifei Biotechnology
.
Jiuan Medical became the "growth king", a year-on-year increase of 319 times
Judging from the three quarterly reports released by Jiuan Medical, in the first three quarters of this year, Jiuan Medical achieved a year-on-year increase of 3010.
77% in revenue of 24.
589 billion yuan, and the net profit attributable to the parent increased by 31918.
64% year-on-year to 16.
050 billion yuan
.
For the significant increase in revenue, Jiuan Medical said in the third quarterly report that it was due to the significant increase
in kit sales.
In the previous third-quarter performance forecast, Jiuan Medical also explained the better performance, saying that during the reporting period, the company's iHealth kit products in the United States market demand was strong, the company actively took various measures to achieve effective operation of production and supply chain, continued to do a good job in order fulfillment and market development, ensured the timely delivery of customer orders, and the company's performance increased
significantly compared with the same period last year.
Mindray achieved a net profit of RMB8.
102 billion
According to the 2022 third quarterly report released by Mindray, in the first three quarters of this year, the company's total revenue was about 23.
3 billion yuan, and the net profit attributable to the parent was about 8.
102 billion yuan, a year-on-year increase of more than 20%.
As for the reasons for the increase in performance, Mindray said that benefiting from the continuous advancement of new medical infrastructure in China and the improvement of the impact of the epidemic on routine business, overseas customers continued to make substantial progress in breakthroughs in high-end customers.
The overseas routine reagent business fully recovered, the installed performance of blockbuster instruments was eye-catching, and the in vitro diagnostics, medical imaging, life information and support businesses all showed growth during the reporting period
.
In the future, Mindray will continue to focus on three business areas, actively expand the seed business with high growth potential, comprehensively strengthen product R&D and innovation, accelerate the reform of the international marketing system, deepen overseas localization construction and other comprehensive capabilities, seize the major opportunities of new domestic medical infrastructure and overseas comprehensive high-end breakthroughs, and continue to enhance the company's product competitiveness.
At the same time, we will continue to improve the quality of internal management and improve operating efficiency to achieve long-term sustained and healthy growth
in operating income and net profit.
WuXi AppTec achieved a bright "report card" and achieved a net profit of 7.
378 billion yuan
According to the third-quarter results report released by WuXi AppTec, the company achieved operating income of RMB 28.
395 billion in the first three quarters of this year, an increase of 71.
87% year-on-year; The net profit attributable to shareholders of listed companies was 7.
378 billion yuan, a year-on-year increase of 107.
12%.
WuXi AppTec is mainly engaged in pharmaceutical R&D and manufacturing outsourcing (CRO/CDMO), empowering pharmaceutical companies to meet the needs of drug discovery, development and manufacturing
.
According to the industry, CXO, as an important segment of the pharmaceutical sector, has undoubtedly achieved WuXi AppTec's bright "report card", especially in an uncertain environment to enhance certainty
.
As for the significant increase in net profit, WuXi AppTec said that through continuous optimization of operating efficiency, capacity utilization rate continued to improve, and the scale effect was further demonstrated, making the growth rate of net profit exceed the growth rate
of revenue in the same period.
In addition, in the previous three quarterly performance forecasts, WuXi AppTec said that the company continued to strengthen WuXi AppTec's integrated CRDMO (contract research, development and production) and CTDMO (contract testing, R&D and production) business models, giving full play to the advantages of global layout, multi-location operations and full industry chain coverage, and timely formulating and efficiently executing business continuity plans to ensure the achievement
of the company's overall performance goals.
Zhifei Biotech achieved a net profit of 5.
607 billion yuan
According to the third quarter performance report released by Zhifei Biotechnology, in the first three quarters of this year, the company achieved operating income of 27.
823 billion yuan and net profit attributable to the parent of 5.
607 billion yuan
.
Zhifei Biotech has formed a R&D strategy of "independent R&D as the mainstay, cooperative R&D as the supplement, and investment incubation as the supplement", and will adhere to the idea of "internationalization of project sources, precision of project selection, pipeline of project development, and localization of project production", and continue to promote R&D innovation, product iteration, and new products to inject new vitality
into development 。 It is reported that at present, Zhifei Biotech has a total of 11 products on the market, 1 product is conditionally listed, including vaccine products to prevent brain flow, cervical cancer, pneumonia, rotavirus and other diseases, and also covers drugs that provide effective solutions for tuberculosis infection screening, prevention and treatment, covering the population including infants and young children, adolescents and adults, providing product support for the prevention and control of a variety of infectious diseases, and also providing diversified disease protection options
for the public.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
